|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Perspectives on new biomarkers in gastric cancer: Diagnostic and prognostic applications显示文摘Gastric cancer is considered one of the most deadly tumors worldwide. Even with the decline in its incidence, the mortality rate of this disease has remained high, mainly due to its late diagnosis and to the lack of precise prognostic markers. The main purpose of this review is to present genetic, epigenetic and proteomic molecular markers that may be used in a diagnostic and prognostic manner and to discuss the pros and cons of each type of marker for improving clinical practice. In this sense, we observed that the use of genetic markers, especially mutations and polymorphisms, should be carefully considered, as they are strongly affected by ethnicity. Proteomic-based markers show promise, but the higher costs of the associated techniques con-tinue to make this approach expensive for routine use. Alternatively, epigenetic markers appear to be very promising, as they can be detected in bodily fluids as well as tissues. However, such markers must be used carefully because epigenetic changes may occur due to environmental factors and aging. Despite the advances in technology and its access, to date, there are few defined biomarkers of prognostic and diagnostic use for gastric tumors. Therefore, the use of a panel of several approaches(genetic, epigenetic and proteomic) should be considered the best alternative for clinical practice. | Danilo do Rosário Pinheiro Wallax Augusto Silva Ferreira Mariceli Baia Leo Barros Mariana Diniz Araújo Symara Rodrigues-Antunes Bárbara do Nascimento Borges | 2014 | World Journal of Gastroenterology2014，20，33： | 4 |
| 2 | ERBIN:A basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor显示文摘 | Borg JP Marchetto S Le Bivic A | 2000 | Nature Cell Biol2000，2，： | 1 |
| 3 | ERBIN: a basolateral PDZ protein that interacts with the mamma- lian ERBB2/HER2 receptor显示文摘 | Borg JP Marchetto S Le Bivic A | 2000 | Nat Cell Biol2000，2，7： | 1 |
| 4 | New protocol of elomiphene citrate treatment in women with hypothalamic amenorrhea显示文摘 | Borges LE Morgante G Musacchio MC | 2007 | Gyneeol Endoerinol2007，23，6： | 1 |
| 5 | Progressive rise in gut hormone levels after Rouxen-Y gastric bypass suggests gut adaptation and explains altered satiety显示文摘 | Borg CM le Roux CW Ghatei MA | 2006 | Br J Surg2006，93，2： | 1 |
| 6 | Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception 显示文摘 | BORGES LE ANDRADE RP ALDRIGHI JM | 2006 | Contraception2006，74，6： | 1 |
| 7 | Activins and related proteins in the establishment of pregnancy显示文摘 | Florio P Gabbanini M Borges LE | 2010 | Reprod Sci2010，17，4： | 1 |
| 8 | Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels显示文摘 | Borg CM le Roux CW Ghatei MA | 2007 | Obes Surg2007，17，9： | 1 |
| 9 | Serum Apoptosis Markers in Acute Liver Failure: A Pilot Study显示文摘 | Anna E. Rutherford Linda S. Hynan Carolina B.S. Borges David G. Forcione Jason T. Blackard Wenyu Lin April R. Gorman Obaid Shakil Shaikh Adrian Reuben Edwyn Harrison K. Rajender Reddy William M. Le Raymond T. Chung | 2007 | Clinical Gastroenterology and Hepatology2007，，12： | 1 |
| 10 | Unusual dermoid cyst in oral cavity显示文摘 | Vieira EM Borges AH Volpato LE | 2014 | Case Rep Pathol2014，2014，38： | 1 |
| 11 | Unusual dermoid cyst in oral cavity显示文摘 | Vieira EM1 Borges AH1 Volpato LE | 2014 | Case Rep Pathol2014，2014，38： | 1 |
| 12 | Activins and related proteins in the establishment of pregnancy显示文摘 | Florio P Gabbanini M Borges LE | 2010 | Reprod Sci2010，17，4： | 1 |
| 13 | Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters显示文摘 | Carel W. le Roux Simon J. B. Aylwin Rachel L. Batterham Cynthia M. Borg Frances Coyle Vyas Prasad Sandra Shurey Mohammad A. Ghatei Ameet G. Patel Stephen R. Bloom | 2006 | Annals of Surgery2006，，1： | 1 |
| 14 | FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer显示文摘AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.METHODS This is a retrospective multicenter cohort, evaluating the efficacy and safety of the association of aflibercept with FOLFIRI3(day 1: aflibercept 4 mg/kg, folinic acid 400 mg/m^2, irinotecan 90 mg/m^2, 5-fluorouracil infusion 2400 mg/m^2 per 46 h; day 3: irinotecan 90 mg/m^2) in patients with previously treated metastatic colorectal cancer. The primary endpoint was overall response rate(ORR). Secondary endpoints were disease control rate(DCR), progression-free survival(PFS), overall survival(OS), and safety.RESULTS Among 74 patients treated in four French centers, nine were excluded due to prior use of aflibercept(n = 3), more than one prior treatment line in irinotecanna?ve patients(n = 3), and inadequate liver function(n = 3). In the 'irinotecan-na?ve' patients(n = 30), ORR was 43.3% and DCR was 76.7%. Median PFS and OS were 11.3 mo(95%CI: 6.1-29.0) and 17.0 mo(95%CI: 13.0-17.3), respectively. The most common(> 5%) grade 3-4 adverse events were diarrhea(37.9%), neutropenia(14.3%), stomatitis and anemia(10.4%), and hypertension(6.7%). In the 'pre-exposed irinotecan' patients(n = 35), 20(57.1%) received ≥ 2 prior lines of treatment. ORR was 34.3% and DCR was 60.0%. Median PFS and OS were 5.7 mo(95%CI: 3.9-10.4) and 14.3 mo(95%CI: 12.8-19.5), respectively.CONCLUSION Minimally modified FOLFIRI has improvement dramatically the FOLFIRI3-aflibercept efficacy, whatever prior use of irinotecan. A prospective randomized trial is warranted to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept. | CANDice Carola Fran?ois Ghiringhelli Stefano Kim Thierry ANDré Juliette Barlet Le?la Bengrine-Lefevre Hélène Marijon Marie-Line Garcia-Larnicol Christophe Borg Linda Dainese Nils Steuer Hubert Richa Magdalena Benetkiewicz Annette K Larsen Aimery de Gramont Benoist Chibaudel | 2018 | World Journal of Clinical Oncology2018，9，5： | 1 |
| 15 | Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm in- faxlts:pharmacokinetics and short-term safety显示文摘 | Ley D Hansen-Pupp I Niklasson A Domellof M Friberg LE Borg J | 2013 | Pediatr Res2013，73，1： | 1 |
| 16 | Activins and related pro- teins in the establishment of pregnancy显示文摘 | Florio P Gabbanini M Borges LE | 2010 | Repred Sci2010，17，4： | 1 |
| 17 | ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor显示文摘 | Borg JP Marchetto S Le Bivic A | 2000 | Nat Cell Biol2000，2，7： | 1 |
| 18 | Income Distribution and Tax Structure: Empirical Test of the Meltzer-Richard Hypothesis显示文摘 | BORGE LE RATTSO J | 2004 | European Economic Review2004，，48： | 1 |
| 19 | Progressive rise in gut hormone levels after Roux-en Y gastric bypass suggests gut adaptation and explains altered satiety显示文摘 | Borg CM le Roux CW Ghatei MA | | 0，，： | 1 |
| 20 | Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptaion and explains altered satiety 显示文摘 | Borg CM le Roux CW Ghatei MA | 2006 | Br J Surg2006，93，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员